Seems like a very simple value proposition. Fits my sweet spot of being scientifically de-risked. Radiotherapy is a very real thing now in other areas, oncology definitely lends itself to it. Can hit both CD 45 and CD 33 and will be able to do both at once as well. Have shown dose response as expected. Side effects superior to alternative treatments. Safe for patients over 60. About a $100 M MC. Tiny company has this therapy in 10 of the largest transplant centers across the US which bodes well if/once approved.
News 
Market Data 
Discover 
AI
